Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR.70/IL15-transduced CB-NK Cells With Chemotherapy for Relapsed/Refractory Hematological Malignancies
NCT05092451Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2022
- Primary completion
- Aug 2030
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CAR.70/IL15-transduced CB-NK cells in B cell lymphoma, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and 8 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Treatment-Related Adverse Events at 1 year, Complete or Partial Response at 30 days and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
CAR.70/IL15-transduced CB-NK cells
03
Conditions
B cell lymphomamyelodysplastic syndrome (MDS)acute myeloid leukemia (AML)multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT05092451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092451.